Dynamic liver dysfunction predicts poor survival in patients with EGFR-mutant non-small cell lung cancer and liver metastases treated with EGFR tyrosine kinase inhibitors.

Abstract excerpt

BACKGROUND: Liver metastasis is an adverse prognostic factor in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). While baseline liver burden is a known risk factor, the prognostic significance of dynamic liver function changes during targeted therapy remains understudied. This study aimed to evaluate the prognostic value of Consecutive Liver Function Abnormalities...

Topics

Join the communities discussing this publication.

• Carcinoma, Non-Small-Cell Lung
• ErbB Receptors
• Liver
• Liver Function Tests
• Liver Neoplasms